{"id":"zd1839-gefitinib","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Diarrhea"},{"rate":"30-50%","effect":"Rash"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-20%","effect":"Dyspnea"},{"rate":"5-20%","effect":"Cough"},{"rate":"5-20%","effect":"Headache"},{"rate":"5-20%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition prevents the activation of downstream signaling pathways that promote cell proliferation and survival, ultimately leading to the death of cancer cells. ZD1839 has been shown to be effective in treating non-small cell lung cancer, particularly in patients with specific EGFR mutations.","oneSentence":"ZD1839 (Gefitinib) is a small molecule that inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:01.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, EGFR mutation positive"},{"name":"Locally advanced or metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07477457","phase":"PHASE2","title":"A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-11","conditions":"Osteosarcoma, Metastasis","enrollment":45},{"nctId":"NCT07458919","phase":"EARLY_PHASE1","title":"Therapy for Advanced NSCLC With EGFR 19delins Mutation","status":"NOT_YET_RECRUITING","sponsor":"Fuzhou General Hospital","startDate":"2026-03-30","conditions":"Lung Cancer","enrollment":94},{"nctId":"NCT07143045","phase":"","title":"A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases","status":"RECRUITING","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2025-12-29","conditions":"EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases","enrollment":800},{"nctId":"NCT03040973","phase":"PHASE2","title":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-23","conditions":"Advanced Solid Tumors Which Are cMET-dependent","enrollment":29},{"nctId":"NCT06675695","phase":"","title":"Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-10-30","conditions":"Non Small Cell Lung Cancer","enrollment":4864},{"nctId":"NCT02411448","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2015-05-06","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":545},{"nctId":"NCT03333343","phase":"PHASE1","title":"Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-01-29","conditions":"EGFR-mutant Non-small Cell Lung Cancer","enrollment":105},{"nctId":"NCT07338396","phase":"","title":"A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":3000},{"nctId":"NCT02296125","phase":"PHASE3","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-03","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer","enrollment":674},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT07271446","phase":"PHASE1","title":"An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer","status":"COMPLETED","sponsor":"Precision Biotech Taiwan Corp.","startDate":"2018-09-01","conditions":"Non-small Cell Lung Cancer","enrollment":8},{"nctId":"NCT02157883","phase":"PHASE1","title":"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-06","conditions":"Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT03122717","phase":"PHASE1, PHASE2","title":"Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-05-09","conditions":"Non-Small Cell Lung Cancer","enrollment":48},{"nctId":"NCT02856893","phase":"PHASE2","title":"Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-10-10","conditions":"NSCLC","enrollment":156},{"nctId":"NCT03653546","phase":"PHASE2, PHASE3","title":"First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases","status":"COMPLETED","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2018-10-29","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases","enrollment":492},{"nctId":"NCT07036016","phase":"","title":"Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2015-01-01","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":67818},{"nctId":"NCT03292133","phase":"PHASE2","title":"A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-10-31","conditions":"Lung Cancer","enrollment":11},{"nctId":"NCT00328562","phase":"PHASE1","title":"ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2003-12","conditions":"Non-Small Cell Lung Carcinoma (NSCLC)","enrollment":13},{"nctId":"NCT03787992","phase":"PHASE3","title":"Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）","status":"ACTIVE_NOT_RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2019-05-30","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer","enrollment":358},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":"Non-Small Cell Lung Cancer","enrollment":5279},{"nctId":"NCT02424617","phase":"PHASE1, PHASE2","title":"A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2015-04-19","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT03944772","phase":"PHASE2","title":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-06-25","conditions":"Non-Small Cell Lung Cancer","enrollment":247},{"nctId":"NCT06071013","phase":"PHASE1, PHASE2","title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2024-02-23","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation","enrollment":20},{"nctId":"NCT06592989","phase":"","title":"A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-30","conditions":"Pancreatic Neuroendocrine Neoplasm, Sorafenib, Gefitinib","enrollment":20},{"nctId":"NCT02588261","phase":"PHASE3","title":"A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-02-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":530},{"nctId":"NCT02347839","phase":"PHASE2","title":"NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2016-01-01","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT04248829","phase":"PHASE3","title":"Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2020-02-13","conditions":"Non-Small Cell Lung Cancer","enrollment":393},{"nctId":"NCT04322890","phase":"PHASE2","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-04-16","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation","enrollment":6000},{"nctId":"NCT03866499","phase":"PHASE3","title":"A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beta Pharma Shanghai","startDate":"2021-04-30","conditions":"NSCLC","enrollment":369},{"nctId":"NCT01513174","phase":"PHASE1, PHASE2","title":"Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2011-08","conditions":"Non Small Cell Lung Cancer","enrollment":186},{"nctId":"NCT04143607","phase":"PHASE3","title":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2019-07-23","conditions":"Locally Advanced or Metastatic NSCLC","enrollment":337},{"nctId":"NCT00198380","phase":"PHASE2","title":"Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2005-04","conditions":"Pneumonic-type Adenocarcinoma (P-ADC), Lung Adenocarcinoma With Bronchiolo-alveolar Feature","enrollment":90},{"nctId":"NCT04401059","phase":"PHASE4","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","status":"RECRUITING","sponsor":"Tian Xie","startDate":"2020-11-09","conditions":"Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma","enrollment":744},{"nctId":"NCT03647592","phase":"","title":"Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Hunan Province Tumor Hospital","startDate":"2018-06-01","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04397432","phase":"","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tian Xie","startDate":"2020-08-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":878},{"nctId":"NCT01185158","phase":"PHASE2","title":"A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2002-05","conditions":"Head and Neck Cancer","enrollment":46},{"nctId":"NCT01485809","phase":"PHASE2","title":"Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy","status":"COMPLETED","sponsor":"Seoul Veterans Hospital","startDate":"2011-10","conditions":"Squamous Cell Carcinoma of Bronchus","enrollment":36},{"nctId":"NCT01774721","phase":"PHASE3","title":"ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-05-09","conditions":"Non-small Cell Lung Cancer With EGFR-Activating Mutations","enrollment":452},{"nctId":"NCT00483561","phase":"PHASE2","title":"Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2004-01","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT00352079","phase":"PHASE3","title":"BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer","status":"TERMINATED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-01-04","conditions":"Bladder Cancer","enrollment":41},{"nctId":"NCT04642547","phase":"NA","title":"Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2020-12-02","conditions":"Hepatocellular Carcinoma, Molecular Targeted Therapy","enrollment":30},{"nctId":"NCT01833572","phase":"PHASE2","title":"Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2013-05","conditions":"Non-small-cell Lung Cancer","enrollment":36},{"nctId":"NCT05934461","phase":"","title":"A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer","status":"COMPLETED","sponsor":"Laibin People's Hospital","startDate":"2014-12-01","conditions":"The Primary Study Metric is Progression-free Survival (PFS)","enrollment":48},{"nctId":"NCT05445791","phase":"PHASE3","title":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2021-07-15","conditions":"Non Small Cell Lung Cancer","enrollment":312},{"nctId":"NCT04179890","phase":"","title":"The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-17","conditions":"Non-squamous, Non-Small Cell Lung Cancer","enrollment":462},{"nctId":"NCT01185171","phase":"PHASE2","title":"Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2003-01-27","conditions":"Head and Neck Cancer","enrollment":70},{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":"Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms","enrollment":36},{"nctId":"NCT01994057","phase":"","title":"A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2012-09","conditions":"Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation","enrollment":1000},{"nctId":"NCT01570296","phase":"PHASE1","title":"A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2011-10-03","conditions":"Non-Small Cell Lung Cancer, Solid Tumors","enrollment":38},{"nctId":"NCT03599518","phase":"PHASE1","title":"DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2018-09-21","conditions":"Non Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT03849768","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2019-02-01","conditions":"Non Small Cell Lung Cancer","enrollment":429},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT01982955","phase":"PHASE1, PHASE2","title":"Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2013-12-23","conditions":"Non-small Cell Lung Cancer","enrollment":88},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT03758287","phase":"PHASE1, PHASE2","title":"Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative","status":"UNKNOWN","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2016-11","conditions":"Non-small Cell Lung Cancer","enrollment":158},{"nctId":"NCT03170180","phase":"PHASE2","title":"Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2017-03-01","conditions":"Stomach Neoplasms","enrollment":66},{"nctId":"NCT02447419","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2014-12-03","conditions":"Solid Tumor","enrollment":16},{"nctId":"NCT00522145","phase":"PHASE2","title":"Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib","status":"COMPLETED","sponsor":"Kadmon Corporation, LLC","startDate":"2007-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":41},{"nctId":"NCT02088112","phase":"PHASE1","title":"MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2014-03-24","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":56},{"nctId":"NCT02932345","phase":"","title":"Gefitinib Long-term Survivor Study","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2016-10-31","conditions":"EGFR Mutation Positive Advanced Non-small-cell Lung Cancer","enrollment":59},{"nctId":"NCT01951469","phase":"PHASE3","title":"Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Non-small Cell Lung Cancer, Brain Metastases, EGFR Mutation","enrollment":160},{"nctId":"NCT03239015","phase":"PHASE2","title":"Efficacy and Safety of Precision Therapy in Refractory Tumor","status":"UNKNOWN","sponsor":"Baodong Qin","startDate":"2017-01-01","conditions":"Rare Tumor, Refractory Tumor","enrollment":300},{"nctId":"NCT00317772","phase":"PHASE1, PHASE2","title":"Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-09-02","conditions":"Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer","enrollment":19},{"nctId":"NCT01288430","phase":"PHASE1","title":"A Study of DS-2248 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2011-03-29","conditions":"Solid Tumors, Non-small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT02736513","phase":"PHASE2","title":"Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2016-05","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT03382795","phase":"PHASE2","title":"Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2018-01-03","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":63},{"nctId":"NCT02804776","phase":"PHASE2","title":"PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2015-01-27","conditions":"Non-small Cell Lung Cancer","enrollment":15},{"nctId":"NCT04874844","phase":"PHASE2, PHASE3","title":"JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety","status":"UNKNOWN","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2021-07-30","conditions":"NSCLC","enrollment":420},{"nctId":"NCT01610336","phase":"PHASE2","title":"A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04-05","conditions":"Non-small Cell Lung Cancer","enrollment":161},{"nctId":"NCT03595644","phase":"PHASE2","title":"Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2017-02-12","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":74},{"nctId":"NCT02025218","phase":"PHASE2","title":"Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-01","conditions":"Lung Cancer","enrollment":21},{"nctId":"NCT02747953","phase":"PHASE2","title":"Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-07","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT02893332","phase":"PHASE3","title":"Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)","status":"TERMINATED","sponsor":"Sichuan Provincial People's Hospital","startDate":"2016-01-15","conditions":"Stage IV EGFR Mutated Non-Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT04390984","phase":"PHASE1","title":"Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-05-26","conditions":"NSCLC","enrollment":22},{"nctId":"NCT01556191","phase":"PHASE2","title":"Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2012-05-15","conditions":"Stage IV Lung Cancer","enrollment":379},{"nctId":"NCT02762877","phase":"","title":"Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Genomic Health®, Inc.","startDate":"2016-04","conditions":"Non Small Cell Lung Carcinoma","enrollment":140},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00052208","phase":"PHASE1, PHASE2","title":"Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-03","conditions":"Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma","enrollment":158},{"nctId":"NCT04575415","phase":"","title":"Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-10-07","conditions":"NSCLC","enrollment":272},{"nctId":"NCT00553254","phase":"PHASE2","title":"Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02-05","conditions":"Carcinoma, Non Small Cell Lung","enrollment":55},{"nctId":"NCT01544179","phase":"PHASE3","title":"A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-03-15","conditions":"Non-Small Cell Lung Cancer","enrollment":265},{"nctId":"NCT03267654","phase":"PHASE2","title":"Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2017-10-12","conditions":"Non-small-cell Lung Cancer","enrollment":100},{"nctId":"NCT03457337","phase":"PHASE2","title":"S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2018-03-28","conditions":"Advanced NSCLC With EGFR Mutation","enrollment":200},{"nctId":"NCT04425187","phase":"PHASE2","title":"Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-06-08","conditions":"PFS","enrollment":120},{"nctId":"NCT04115410","phase":"","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-07-01","conditions":"Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events","enrollment":4724},{"nctId":"NCT02374645","phase":"PHASE1","title":"A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2015-04","conditions":"Non-Small Cell Lung Cancer","enrollment":64},{"nctId":"NCT04358562","phase":"PHASE2","title":"Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2020-05-01","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation","enrollment":240},{"nctId":"NCT01466660","phase":"PHASE2","title":"LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-12-13","conditions":"Lung Neoplasms","enrollment":319},{"nctId":"NCT00025116","phase":"PHASE2","title":"ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2001-04-24","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT03119519","phase":"PHASE2","title":"Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.","status":"UNKNOWN","sponsor":"Southern Medical University, China","startDate":"2017-12-11","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":148},{"nctId":"NCT01405079","phase":"PHASE3","title":"Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2011-09-19","conditions":"Non-small Cell Lung Cancer","enrollment":222},{"nctId":"NCT01933347","phase":"PHASE2","title":"Third-line Treatment of Gefitinib in NSCLC Patients","status":"COMPLETED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2014-04-07","conditions":"Non Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT04239833","phase":"PHASE3","title":"A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2020-01-31","conditions":"Non-Small Cell Lung Cancer","enrollment":240},{"nctId":"NCT02416739","phase":"PHASE2, PHASE3","title":"Anticancer Activity of Nicotinamide on Lung Cancer","status":"UNKNOWN","sponsor":"Il Yeong Park, Ph.D.","startDate":"2015-03","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":110},{"nctId":"NCT02745691","phase":"","title":"Psychometric Properties of the EORTC QLQ-LC29","status":"COMPLETED","sponsor":"University Hospital Regensburg","startDate":"2016-04-01","conditions":"Lung Cancer","enrollment":523},{"nctId":"NCT04193007","phase":"PHASE2","title":"The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2019-12-01","conditions":"Non Small Cell Lung Cancer, Brain Metastases","enrollment":100},{"nctId":"NCT03529084","phase":"PHASE3","title":"Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-24","conditions":"Carcinoma, Non-small Cell Lung","enrollment":""},{"nctId":"NCT02976116","phase":"PHASE2","title":"A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2016-12","conditions":"NSCLC","enrollment":50},{"nctId":"NCT04028778","phase":"PHASE3","title":"Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-04-10","conditions":"Lung Cancer, Nonsmall Cell","enrollment":310},{"nctId":"NCT00014183","phase":"PHASE2","title":"ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2001-01","conditions":"Kidney Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL RIGIDITY"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"COLON CANCER"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":1,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":1,"reaction":"METASTASES TO LUNG"},{"count":1,"reaction":"METASTASES TO THORAX"},{"count":1,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":8284,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Iressa"],"phase":"phase_3","status":"active","brandName":"ZD1839 (Gefitinib)","genericName":"ZD1839 (Gefitinib)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ZD1839 (Gefitinib) is a small molecule that inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. Used for Non-small cell lung cancer, EGFR mutation positive, Locally advanced or metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}